Physician profile
Amy Ahnert
NPI 1245260587
$1,125.57
in general payments reported to CMS, 2019-2025
21 companies · $339 in 2025
The $339 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153 · 2022: $139 · 2023: $146 · 2024: $347 · 2025: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $833.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $832.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $285.37 | 2022-2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Abiomed | $146.10 | 2025 | |
| Medtronic Vascular, INC. | $94.59 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $65.24 | 2024 | |
| Amgen INC. | $64.90 | 2024-2025 | Repatha |
| Astrazeneca Pharmaceuticals Lp | $57.25 | 2019-2025 | Farxiga |
| Boston Scientific Corporation | $48.00 | 2019 | |
| Heartflow, INC. | $43.65 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.57 | 2025 | |
| Genzyme Corporation | $41.44 | 2024 | |
| Novartis Pharmaceuticals Corporation | $30.71 | 2024-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $30.52 | 2024 | Arcalyst |
| Esperion Therapeutics, INC. | $29.70 | 2025 | Nexletol |
| Baxter Healthcare | $25.47 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Amicus Therapeutics, INC. | $22.77 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $17.23 | 2024 | Verquvo |
| Janssen Pharmaceuticals, INC | $17.00 | 2024 | Xarelto |
| Pfizer INC. | $17.00 | 2025 | |
| Sanofi-Aventis U.S. LLC | $16.88 | 2024 | |
| Azurity Pharmaceuticals, INC. | $16.05 | 2024 | Edarbyclor |
| E.R. Squibb & Sons, L.L.C. | $14.13 | 2025 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Ahnert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.